当前位置：药药网 / 数据中心 / 临床注释-2,变异和临床注释数据
氯吡格雷
临床注释ID
1451282440
药物名称(英)
clopidogrel
变异单倍型
CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*8, CYP2C19*17
基因
CYP2C19
证据级别
1A
水平覆盖
水平修饰符
Tier 1 VIP
表现型类别(英)
Efficacy;Toxicity
表现型类别
功效；毒性
分数
380.25
PMID计数
62
计数的证据
117
表现型
急性冠状动脉综合征；心血管疾病；短暂性脑缺血发作；中风
表现型(英)
Acute coronary syndrome;Cardiovascular Diseases;Ischemic Attack, Transient;Stroke
最新日期
2022/1/19 0:00:00
URL
https://www.pharmgkb.org/clinicalAnnotation/1451282440
专业人口(英)
专业人口
临床等位基因
id等位基因注释文本
1349 *17 The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.
1348 *8 The CYP2C19*8 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*8 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.
1347 *6 The CYP2C19*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*6 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.
1346 *5 The CYP2C19*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*5 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.
1345 *4 The CYP2C19*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*4 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.
1344 *3 The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.
1343 *2 The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.
1342 *1 The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with a normal function allele who are treated with clopidogrel may have a decreased, but not absent, risk for adverse cardiac and cerebrovascular events as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.
临床证据
id证据的ID总结
4082 1450370889 CYP2C19 *1/*1 (assigned as normal metabolizer phenotype phenotype) is not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*2 + *2/*2 + *2/*17 + *17/*17 + *1/*17.
4081 1449751959 CYP2C19 *3/*17 is associated with Thrombosis when treated with aspirin and clopidogrel.
4080 1449187720 CYP2C19 *2 is not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.
4079 1449187703 CYP2C19 *3 is associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.
4078 1448631958 CYP2C19 *2 is associated with increased risk of adverse cardiovascular events when treated with clopidogrel as compared to CYP2C19 *1/*1.
4077 1448631945 CYP2C19 *2 + *3 are not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.
4076 1448624845 CYP2C19 *2 is not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*2.
4075 1448617742 CYP2C19 *2 + *3 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.
4074 1448617264 CYP2C19 *2 + *3 + *8 are associated with increased risk of composite endpoints (stroke, myocardial infarction, or vascular death) when treated with clopidogrel in people with Ischemic Attack, Transient and Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.
4073 1448617237 CYP2C19 *2 + *3 + *8 are associated with increased risk of Stroke when treated with clopidogrel in people with Ischemic Attack, Transient or Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.
4072 1448603394 CYP2C19 *2 is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.
4071 1448602737 CYP2C19 *2 + *3 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.
4070 1448257000 CYP2C19 *2 + *3 are not associated with likelihood of Hemorrhage when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.
4069 1448101486 CYP2C19 *2 is associated with decreased metabolism of clopidogrel in men with Coronary Artery Disease as compared to CYP2C19 *1.
4068 1447949788 CYP2C19 *1/*2 + *2/*2 are associated with increased likelihood of adverse events when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.
4067 1447678787 CYP2C19 *1/*2 + *2/*3 + *1/*3 + *2/*17 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.
4066 1446899985 CYP2C19 *2 is associated with increased likelihood of Stroke when exposed to aspirin and clopidogrel in people with Stroke as compared to CYP2C19 *1 + *17.
4065 1446899112 CYP2C19 *2 + *4 are associated with increased risk of Myocardial Infarction when treated with clopidogrel as compared to CYP2C19 *1 + *17.
4064 1446899082 CYP2C19 *2 + *4 are not associated with risk of Death, Ischemic Attack, Transient, Stroke or Thrombosis when treated with clopidogrel as compared to CYP2C19 *1 + *17.
4063 1444706496 CYP2C19 *2 + *3 is associated with increased risk of Cardiovascular Diseases when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.
4062 1444706464 CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of Cardiovascular Diseases when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.
4061 1444704559 CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.
4060 1444704529 CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers phenotype) are not associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .
4059 1444704497 CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers phenotype) are associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .
4058 1444704450 CYP2C19 *2 + *3 are associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.
4057 1444702878 CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of Cardiovascular Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1.
4056 1444701909 CYP2C19 *2 is associated with increased risk of when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.
4055 1444667831 CYP2C19 *2/*2 + *3/*3 + *2/*3 (assigned as poor metabolizers phenotype) are associated with increased risk of Cardiovascular Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .
4054 1444667802 CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are associated with increased risk of Cardiovascular Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .
4053 1184987748 CYP2C19 *2 is associated with increased resistance to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.
4052 1184987695 CYP2C19 *3 is associated with increased risk of Thrombosis when treated with clopidogrel as compared to CYP2C19 *1.
4051 1184467283 CYP2C19 *2/*2 + *1/*2 is associated with increased likelihood of major adverse cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.
4050 1184349821 CYP2C19 *9 is not associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.
4049 1184349747 CYP2C19 *2 is associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.
4048 1184349711 CYP2C19 *2 is not associated with increased risk of all-cause mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.
4047 1184349702 CYP2C19 *2 is associated with increased risk of all-cause mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.
4046 1184349692 CYP2C19 *2 + *3 are not associated with increased risk of Mortality when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.
4045 1184349679 CYP2C19 *2 + *3 are associated with increased risk of ischaemic stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.
4044 1184349669 CYP2C19 *2 + *3 are associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.
4043 1184349659 CYP2C19 *2 + *3 are associated with increased risk of adverse clinical events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.
4042 1184349649 CYP2C19 *2 + *3 are associated with increased risk of adverse clinical events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.
4041 1184349639 CYP2C19 *2 + *3 are associated with increased risk of adverse clinical events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.
4040 1184349625 CYP2C19 *2 + *3 are associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.
4039 1184348964 CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are not associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.
4038 1184348948 CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.
4037 1183705616 CYP2C19 *2 + *3 are associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 *1/*1.
4036 1183681542 CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3 + *2/*17 + *3/*17.
4035 1183681419 CYP2C19 *2/*2 + *2/*3 + *3/*3 is not associated with risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3 + *2/*17 + *3/*17.
4034 1183681384 CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3 + *2/*17 + *3/*17.
4033 1183681338 CYP2C19 *1/*17 + *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is not associated with risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1.
4032 1183681314 CYP2C19 *1/*2 is not associated with risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.
4031 1183681306 CYP2C19 *2/*3 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.
4030 1183681283 CYP2C19 *2/*2 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.
4029 1043880590 CYP2C19 *5 is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.
4028 1043880576 CYP2C19 *5 is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.
4027 1043880487 CYP2C19 *8 is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.
4026 1043880481 CYP2C19 *6 is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.
4025 1043858934 CYP2C19 *4 is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.
4024 982023672 CYP2C19 *3 is associated with increased risk of stent thrombosis when treated with clopidogrel as compared to CYP2C19 *1.
4023 982023666 CYP2C19 *2 is associated with increased risk of stent thrombosis (ST) after 1 year when treated with clopidogrel as compared to CYP2C19 *1.
4022 981755473 CYP2C19 *1/*3 + *2/*3 is associated with increased risk of recurrent cardiovascular (CV) events 1 year after PCI in Chinese patients when treated with clopidogrel as compared to CYP2C19 *1/*1.
4021 981755468 CYP2C19 *1/*2 + *2/*2 is associated with increased risk of recurrent cardiovascular (CV) events 1 year after PCI in Chinese patients when treated with clopidogrel as compared to CYP2C19 *1/*1.
4020 981500454 CYP2C19 *2 is associated with increased risk of major adverse cardiovascular events and stent thrombosis when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.
4019 981483641 CYP2C19 *3 is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1.
4018 981483636 CYP2C19 *2 is associated with increased risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1.
4017 981478617 CYP2C19 *3 is associated with increased risk of composite ischemic events when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.
4016 981478613 CYP2C19 *2 is associated with increased risk of composite ischemic events when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.
4015 981352424 CYP2C19 *5 is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.
4014 1450112843 Genotypes AA + AG are not associated with increased likelihood of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.
4013 1449732819 Genotypes AA + AG are associated with increased major adverse cardiac events (mace) when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.
4012 1449310942 Allele A is associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele G.
4011 1184472125 Genotypes AA + AG is associated with increased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotype GG.
4010 769146308 Allele A is not associated with cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.
4009 769146043 Allele A is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.
4008 769146034 Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with percutaneous coronary intervention as compared to allele G.
4007 769146008 Allele A is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.
4006 655388276 Allele A is associated with increased risk of cardiovascular event when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.
1335 769258868 Genotype AA is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.
1334 827814610 Allele A is associated with higher composite har outcome (cardiac death, non fatal myocardial infarction and stent thrombosis) up to 12 months' follow up when treated with aspirin and clopidogrel in people with drug-eluting stents as compared to allele G.
1333 1043763118 Genotypes AA + AG are associated with increased risk of cardiovascular events when treated with clopidogrel as compared to genotype GG.
1332 1028218721 Genotypes AA + AG are associated with increased risk of stent thrombosis when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to genotype GG.
1331 1027950849 Allele A is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.
1330 1027543294 Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.
1329 982035437 Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.
1328 982033160 Genotypes AA + AG are associated with decreased platelet function when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.
1327 982028928 Allele A is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.
1326 981843646 Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele G.
1325 981843612 Genotype AG is not associated with increased risk of primary clinical endpoint of death due to cardiovascular causes, non-fatal MI or stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.
1324 981843601 Genotype AA is associated with increased risk of primary clinical endpoint of death due to cardiovascular causes, non-fatal MI or stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.
1323 981843514 Genotype AA is associated with increased risk of ischemic events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.
1322 981843499 Genotype AA is associated with increased risk of major cardiovascular events (MACE) at 1 year when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.
1321 981802954 Genotype AA is associated with increased risk of composite outcome of non-fatal MI, all cause death and stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.
1320 981802939 Genotype AA is associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.
1319 981794408 Allele A is associated with increased risk of major cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.
1318 981344397 Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.
1317 981239613 Genotype AA is associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to genotypes AG + GG.
1316 982035455 Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.
1315 982032530 Allele A is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.
1314 982028939 Allele A is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.
1313 981352394 Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.
1312 981344417 Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.
1311 982032538 Allele G is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele A.
1310 982028948 Allele G is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele A.
1309 981352416 Allele G is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype AA.
1308 1449310952 Allele T is associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele C.
1307 1184472133 Genotypes CT + TT is associated with decreased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotype CC.
1306 769146312 Allele T is associated with decreased cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome.
1305 1043818242 Genotype CT is not associated with increased risk of cardiovascular events when treated with clopidogrel in patients undergoing percutaneous coronary intervention (PCI) as compared to genotype CC.
1304 1043818236 Genotype CT is not associated with increased risk of stent thrombosis when treated with clopidogrel in patients undergoing percutaneous coronary intervention (PCI) as compared to genotype CC.
1303 1043818226 Genotype CT is not associated with bleeding events when treated with clopidogrel in patients undergoing percutaneous coronary intervention (PCI) as compared to genotype CC.
1302 981843680 Allele T is not associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele C.
1301 981843458 Allele T is associated with decreased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.
1300 1451116983 CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with percutaneous coronary intervention.
1299 1449140365 CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel.
1298 1183699694 CYP2C19 normal metabolizers are associated with decreased risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 poor metabolizers and intermediate metabolizers.
1297 PA166104956 Annotation of DPWG Guideline for clopidogrel and CYP2C19
1296 PA166104948 Annotation of CPIC Guideline for clopidogrel and CYP2C19
临床病史
id类型评论
1498 Update combined with CA 1446900036 (clopidogrel; Ischemic Attack, Transient and Stroke; risk for secondary events)
1497 Update changed cardiovascular events to cardiac and cerebrovascular events
1496 Update Added DPWG guideline.
1495 Update CA score added as part of scoring system release. LOE assigned following curator review.
1494 Create Created
1493 Update combined clopidogrel only and 'aspirin and clopidogrel' VAs given that clopidogrel is generally given in combination with aspirin; PA982028896; PA981201917, PA655384520 are merged into this annotation

最新招商产品更多>>

网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈
免责声明：以上所展示的信息由企业自行提供，内容的真实性、准确性和合法性由发布企业负责，医药网对此不承担任何责任。
相关链接：医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究　　客服热线：0575-83552251 / 13754370441  QQ客服：药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　浙公网安备:330683240604819103159
　医药代理商群１：药药网药品采购交流医药代理商群２：药药网药品采购交流2医药代理商群３：药药网药品采购交流3